A CLINICAL RESEARCH ON UTHIRAVATHA SURONITHAM (RHEUMATOID ARTHRITIS) WITH SIDDHA DRUG VATHA RATCHASAN MATHTHIRAI

AN OPEN CLINICAL STUDY ON UTHIRAVATHA SURONITHAM (RHEUMATOID ARTHRITIS)WITH THE EVALUATION OF SIDDHA TRIAL DRUG VATHA RATCHASAN MATHTHIRAI

Status

Recruiting

Phases

Phase 2

Study type

Observational

Source

CTRI

Registry ID

CTRI/2017/11/010357

Enrollment

Registered

2017-11-02

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- MALE AND FEMALE WITH MORNING STIFFNESS AND THREE OR MORE JOINT PAIN

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Age 18 to 50 years Willing to participate in trial and signing in consent proforma History of Rheumatoid Arthritis (Anti CCP and RA positive) Morning stiffness Three or more join pain Swelling

Exclusion criteria

Exclusion criteria: Rheumatic fever Psoriatic arthropathica Gouty arthritis Systemic lupus erythematous H/O of Sulphur allergy Progressive systemic sclerosis(PSS)

Design outcomes

Primary

Measure	Time frame
It mainly assessed by reduce symptoms like pain swelling morning stiffness Hopefully it brings prognostic changes in CRP RA factor X rayTimepoint: 48 days	—

Secondary

Measure	Time frame
Secondary outcome is assessed by comparing the safety parameterss before and after treatmentTimepoint: 48 days	—

Countries

India

Contacts

Public ContactDR P PARTHIBHAN

GOVERNMENT SIDDHA MEDICAL COLLEGE

drkkanakavalli@gmail.com9444122865

Outcome results